readthroughSign in
Nov 12, 2026Quarterly update

Spero reports Q3 2026 results, plans SP001 Phase 2 in IgG4-RD for Q2 2027

Spero said cash of $107.9 million should fund operations into the second half of 2029 as it advances its in-licensed CD40L antibody toward a mid-2027 Phase 2 start.

Spero Therapeutics reported third quarter 2026 financial results and a business update on November 12, 2026. The company said its lead asset, SP001, is slated to begin a Phase 2 study in IgG4-related disease (IgG4-RD) in the second quarter of 2027.1

SP001 came to Spero through a licensing deal. The company said that in July 2026, Spero obtained exclusive worldwide rights from affiliates of Innovent Biologics, Inc. to research, develop, manufacture, and commercialize the antibody, with Greater China excluded from the territory.1 SP001 is described as a third-generation, fully humanized, Fc-silent IgG1 monoclonal antibody targeting CD40L.1 Supporting clinical work to date includes Phase 1 single and multiple ascending dose studies in healthy volunteers run by Innovent, along with a Phase 1b multiple ascending dose study in patients with primary Sjögren's disease conducted in China.1 Spero noted that the Phase 1b data were presented at the EULAR 2026 Congress.1

On financing, Spero said that in July 2026 it closed a $105 million non-recourse, non-dilutive milestone and royalty financing with affiliates of HealthCare Royalty Partners, a business of KKR, in exchange for a portion of anticipated Utebzi payments owed to Spero by GSK.1 The company added that it retains a 35% interest in any GSK payments left after required note payments to HCRx are made.1

On personnel, Spero said it named Debra Jeske Zack, M.D., Ph.D. as Chief Medical Officer in July 2026 to lead clinical development,1 and also appointed William Ho, M.D., Ph.D. to its Board of Directors and Development Committee effective November 10, 2026,1 while Dr. Patrick Vink stepped down from the Board after eleven years of service.1

On cash, Spero reported cash and cash equivalents of $107.9 million as of September 30, 2026, which it said should be sufficient to fund operating expenses and capital expenditures into the second half of 2029.1

Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.